Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 6/20 | 0.39 |
| ▸ | AKT2 | P31751 | 6/20 | 0.39 |
| ▸ | MLNR | O43193 | 11/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | GHSR | Q92847 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3725181 | 0.91 | AKT1 (0.40) | AKT1AKT2MLNR | |
| SCHEMBL3723604 | 0.86 | ABL1 (0.46) | AKT1AKT2TGFBR1 | |
| SCHEMBL3718092 | 0.84 | DRD2 (0.41) | AKT1AKT2TGFBR1 | |
| SCHEMBL3716702 | 0.83 | DRD2 (0.40) | AKT1AKT2TGFBR1 | |
| SCHEMBL3715980 | 0.83 | ACVR1 (0.41) | AKT1AKT2TGFBR1 | |
| SCHEMBL3723005 | 0.82 | ABL1 (0.37) | AKT1AKT2TGFBR1CYP2D6 | |
| SCHEMBL3719755 | 0.79 | TBK1 (0.44) | — | |
| SCHEMBL3725367 | 0.76 | DRD2 (0.41) | TGFBR1 | |
| SCHEMBL3718535 | 0.75 | GHSR (0.42) | TGFBR1GHSR | |
| SCHEMBL3722316 | 0.75 | ACVR1B (0.43) | TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2242742-B1 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-12-02 | — | — | EP | disclosed |
| US-8343966-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-01-01 | — | — | US | disclosed |
| EP-2242742-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2010-10-27 | — | — | EP | disclosed |
| US-20090215776-A1 | Organic compounds | ADCOCK CLAIRE | 2009-08-27 | — | — | US | disclosed |
| WO-2009087212-A2 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215776-A1 | Organic compounds | REN, RXFP1, MYLK | AKT1 2658/4885AKT2 2471/4885MLNR 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.